Skip to main content
Clinical Trials/NCT05509166
NCT05509166
Recruiting
N/A

A Unified Protocol to Address Sexual Minority Women's Minority Stress, Mental Health and Hazardous Drinking

Yale University1 site in 1 country450 target enrollmentFebruary 1, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heavy Drinking
Sponsor
Yale University
Enrollment
450
Locations
1
Primary Endpoint
Change in heavy drinking
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The purpose of this 2-arm randomized controlled trial is to assess the efficacy of a 10-session lesbian, gay, bisexual, transgender, and queer (LGBTQ)-affirmative cognitive-behavioral psychotherapy (CBT) delivered via telehealth in a large sample of sexual minority women (SMW) in New York, New Jersey and Pennsylvania. The investigators will assess whether the EQuIP (Empowering Queer Identities in Psychotherapy) treatment demonstrates significant reductions in heavy drinking (HD) and mental health symptoms (e.g., depression) compared to LGBTQ-affirmative treatment-as-usual.

Detailed Description

The purpose of this study is to assess the efficacy of a 10-session LGBTQ-affirmative cognitive behavioral psychotherapy (CBT) delivered via telehealth in a large sample of sexual minority women (SMW) in New York, New Jersey and Pennsylvania. The treatment, EQuIP (Empowering Queer Identities in Psychotherapy), uses a CBT-based transdiagnostic approach to target the common cognitive, affective, and behavioral responses to minority stress that lead to mental and behavioral health disparities for sexual minority women. We will assess in a 2-arm randomized controlled trial (RCT) whether the EQuIP treatment demonstrates significant reductions in heavy drinking (HD) and mental health symptoms (e.g., depression) compared to LGBTQ-affirmative Treatment-As-Usual. The investigators will assess whether psychosocial mechanisms (e.g., emotion dysregulation) mediate reductions in heavy drinking and separately and identify whether EQuIP is differentially efficacious across key demographic factors.

Registry
clinicaltrials.gov
Start Date
February 1, 2023
End Date
August 1, 2027
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • be 18 years of age or older
  • be fluent in English
  • self-identify as lesbian, bisexual, queer, pansexual, or other non-heterosexual identity
  • report at ≥ 8 standard drinks/week, on average, in the past 30 days, OR report at least 2 heavy drinking days ( ≥ 4 drinks in one day) in the past 30 days 4) currently experience a Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 depression or anxiety disorder (screened initially using a cutoff of ≥ 2 on the Brief Symptom Inventory-4 and further confirmed by diagnostic interview via the DIAMOND) 5) report at least minimum motivation to reduce drinking (measured by the Readiness Ruler) 6) live in New York, New Jersey, and Pennsylvania and planning to stay for at least the next 4 months

Exclusion Criteria

  • report current mental health treatment ≥1 day/mo
  • report having received any CBT in the past 3 months
  • report current alcohol or drug abuse treatment, except mutual self-help (e.g., Alcoholics Anonymous)
  • need alcohol detoxification indicated by ≥9 on Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar)
  • exhibit active psychosis or active mania, as assessed by the Structured Clinical Interviews for DSM-5 Disorders (SCID) Psych Screen
  • exhibit active suicidality or active homicidality, as assessed by the SCID-Psych Screen
  • be currently legally mandated to attend treatment
  • demonstrate gross cognitive impairment, as assessed with the Telephone Interview for Cognitive Status

Outcomes

Primary Outcomes

Change in heavy drinking

Time Frame: Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up

The proportion of heavy drinking days will be assessed using a 30-day Timeline Followback. The Timeline Followback is a structured interview that will assess alcohol use over the past 30 days. Heavy drinking days are defined as those in which more than four drinks were consumed within a two-hour period.

Secondary Outcomes

  • Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND)(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Depression Symptom Severity(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Anxiety Symptom Severity(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Overall Depression Severity and Impairment Scale (ODSIS)(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Overall Anxiety Severity and Impairment Scale (OASIS)(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • PTSD symptoms(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Effects of Alcohol Use(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Frequency of Alcohol Use(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Suicidal Ideation(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Mental Health Symptom Presence and Severity(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Alcohol Use(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Alcohol Self-Efficacy(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Drug Use and Drug-Related Problems(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)
  • Cannabis Use and Cannabis-Related Problems(Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-up)

Study Sites (1)

Loading locations...

Similar Trials